Biotop-report 2014
Yüklə 0,7 Mb. Pdf görüntüsü
|
28 BioTOPics 47 | May 2014 BioTOP-Report 2014 Evestra GmbH Evestra GmbH, founded in July 2008, is a fully owned subsidiary of Evestra Inc. located in San Antonio Texas. Evestra GmbH serves as the development and commercialization center for Europe and ROW. Evestra’s mis- sion is to develop and commercialize steroid- based female healthcare products. The development strategy of the company includes product ideas with known com- pounds as well as New Chemical Entities. Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical need areas of wom- en’s health such as hormonal-dependent breast cancer and endometriosis. The com- pany is also pursuing different projects in fertility control, e.g. a new estrogen for oral contraception, with superior pharmacologi- cal properties compared to the standard drug ethinyl estradiol. Several patents on new composition of mat- ter, new technical processes and use patents have been filed during the last years and support the strong intellectually property position. Evestra is concentrating on R&D and will seek more partners for commercial- ization. More detailed information can be found on our website. Address
Evestra GmbH Britzer Straße 26 12439 Berlin · Germany EU Contact Prof. Klaus Nickisch · Managing Director Phone +49 30 66509642 knickisch@evestra.com www.evestra.com LGC Genomics At LGC we offer a full range of high quality PCR reagents, custom genotyping assays, genomic services and workflow solutions for DNA sample preparation and downstream processing (www.lgcgroup.com/genomics). Our proprietary KASP™ allelic discrimination chemistry and has optimised workflows for 1536 microtitre plates that enable assay min- iaturisation for more flexible, cost-effective workflow solutions in high-throughput geno- typing. In addition, customers are offered industry leading proprietary nucleic acid extraction, sequencing and genotyping ser- vices from our labs globally. „We use what we sell and sell what we use” is key to the products and services we pro- vide.
Our portfolio includes:
k Genotyping services, assays and reagents
k
services
k DNA and RNA extraction products and services
k
k Laboratory instrumentation k Plate sealers k Liquid handling robots k High-throughput PCR thermal cyclers k Plate readers We operate sales offices in the UK, Germany and the USA, with sales representatives throughout Europe, the USA and Australia as well as distributors in China, Korea and other key emerging territories. Address
LGC Genomics GmbH Ostendstrasse 25 · TGS Haus 8 12459 Berlin · Germany Phone +49 30 53042200 genomics@lgcgroup.com www.lgcgroup.com/genomics 29 BioTOPics 47 | May 2014 BioTOP-Report 2014 Metanomics Health GmbH Metanomics Health – a BASF Group compa- ny – combines comprehensive Metabolite Profiling (metabolomics) with biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and xenobiotic metabolites in biological systems. The core expertise of Metanomics Health resides in discovery and validation of biomarkers. Technologies
k
than 75 GC-MS and LC-MS/MS instru- ments
k Wide metabolite coverage via combina- tion of unbiased and targeted platforms
k Unique tox mode of action prediction through MetaMap ® Tox database k Excellence in systems correlation analy- sis of complex gene function relation- ships
k Highly robust and reproducible results Major R&D-Topics In cooperation with academic institutes and clinical experts Metanomics Health is run- ning a large-scale diagnostic biomarker pro- gram. Areas include metabolic syndrome, heart failure, prostate cancer and pancreatic cancer to mention a few. Market Segments Metanomics Health provides its services to pharmaceutical, diagnostics and nutrition companies. Technology applications include:
k Mechanism of action studies
k Mechanism of toxicity studies
k Translational and clinical biomarker development (e.g. PK/PD, patient stratifi- cation, efficacy and safety markers)
k Companion diagnostic development
k Cell culture & bioprocess optimization
k Biospecimen quality control Address
Metanomics Health GmbH Tegeler Weg 33 · 10589 Berlin · Germany Contact Dr. Tim Bölke · Managing Director Phone +49 30 34807 400 Fax
+49 30 34807 401 company.info@metanomics-health.de www.metanomics-health.de nanoPET Pharma GmbH nanoPET is a biopharmaceutical company specialized on R&D, manufacturing and mar- keting of innovative drug substances for Diagnostic Imaging. We focus on relevant cardiovascular, oncological and neurological indications as well as on regenerative medi- cine. Nanotechnology is a key element of our business. We operate in three major areas. The first nanoparticular tracers for clinical PET: nanoPET prepares the clinical develop- ment of its patented technology platform: inorganic nanoparticular tracers for cell- and molecular-specific positron emission tomog- raphy (PET). Viscover™ imaging agents – a landmark in small animal imaging: As animal imaging is rapidly gaining relevance in pharmaceutical research, we are delighted to offer you an exciting portfolio of specialized pre-clinical imaging agents covering the principal imag- ing modalities (MRI, CT, Ultrasound, Optical Imaging, SPECT & PET). Get a detailed insight into our product portfolio and down- load a free copy of our imaging guide on www.viscover.com Consulting and Service tailored to your needs: As a technology and service provider, we offer our expertise to biopharmaceutical companies and imaging equipment manu- facturers. Our customers benefit from the long-standing industry expertise our team has attained in the pharmaceutical research & development. Address
nanoPET Pharma GmbH Robert-Koch-Platz 4 10115 Berlin · Germany Contact
Dr. Andreas Briel · CEO Phone +49 30 890 49740 imaging@nanopet-pharma.com www.nanopet-pharma.com Yüklə 0,7 Mb. Dostları ilə paylaş:
|